Prescription

SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Amylyx

Retrieved on: 
Thursday, March 28, 2024
Patient, LLP, Prescription, IBD, Investor's Business Daily, Amylyx Pharmaceuticals, Advertising, Court, BBC World Service, Evercore, Pharmaceutical industry

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia.

Key Points: 
  • Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia.
  • The firm has recovered hundreds of millions of dollars for investors since its founding in 1995.
  • Faruqi & Faruqi, LLP also encourages anyone with information regarding Amylyx’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
  • The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com).

The Oncology Institute Reports Fourth Quarter and Full Year 2023 Financial Results and Guidance for 2024

Retrieved on: 
Wednesday, March 27, 2024
Growth, Prescription, Earnout, Depreciation, Eastern Time Zone, PMPY, FFS, Pharmaceutical industry

Consolidated revenue for Q4 2023 was $86 million, an increase of 20.1% compared to Q4 2022, and a 4.6% increase compared to Q3 2023.

Key Points: 
  • Consolidated revenue for Q4 2023 was $86 million, an increase of 20.1% compared to Q4 2022, and a 4.6% increase compared to Q3 2023.
  • Gross profit in Q4 2023 was $14 million, a decrease of 8.0% compared to Q4 2022.
  • Gross profit is calculated by subtracting direct costs of patient services, dispensary, and clinical trials and other from consolidated revenues.
  • TOI will host a conference call on Wednesday, March 27, 2024 at 5:00 p.m. (Eastern Time) to discuss fourth quarter and full year results and management’s outlook for future financial and operational performance.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Cassava, NYCB, Amylyx, and InMode and Encourages Investors to Contact the Firm

Retrieved on: 
Tuesday, March 26, 2024
Apoptosis, Patient, AMX0035, Science, New York Community Bank, NYCB, P.C, Initiative, ACL, Scientific misconduct, IBD, Confidentiality, Safety, Injury, Data management, Food, Signature, Cassava Sciences, ALS, Alzheimer's disease, Defendant, Food and Drug Administration, Journal, Amyotrophy, News, Prescription, Amylyx Pharmaceuticals, Dentist, FDA, City University, Biomarker, Dermatology, Complaint, Investor's Business Daily, Neurobiology of Aging, Cognition, Assumption, Category, BBC World Service, Evercore, Cassava, Pharmaceutical industry

The Company's lead therapeutic drug candidate is PTI-125 (or "simufilam"), a small molecule drug for the proposed treatment of Alzheimer's disease.

Key Points: 
  • The Company's lead therapeutic drug candidate is PTI-125 (or "simufilam"), a small molecule drug for the proposed treatment of Alzheimer's disease.
  • However, in response, Cassava denied the allegations in the Citizen Petition and instead touted the effectiveness of simufilam and the efficacy of the Company's research programs.
  • On this news, Cassava's stock price fell $2.68 per share, or 15.28%, to close at $14.86 per share on October 13, 2023.
  • For more information on the InMode class action go to: https://bespc.com/cases/INMD

Blain’s Farm & Fleet’s AnimalRX: A Timely Solution for Dairy & Meat Farmers amidst the Shifting Animal Medication Landscape

Retrieved on: 
Tuesday, April 9, 2024
FDA, Retail, Health, Consumer, Other Health, Online Retail, Pharmaceutical, Other Natural Resources, Other Retail, Agriculture, Specialty, Natural Resources, Veterinary, Pets, KitchenAid, Blain, Farmer, General store, Cub Cadet, Cuisinart, Farm, Roundup (herbicide), Livestock, Craftsman, Minwax, Prescription, Tefal, Blain's Farm & Fleet, Briggs & Stratton, OTC, GFI, JMF, DeWalt, Fiskars, Pet, Char-Broil, Multimedia, Animal, Graco, MTD Holdings, Dairy

This change now requires these medications, such as Oxytetracycline, Sulfisoxazole, Erythromycin, and others to be obtained with a prescription from a licensed veterinarian.

Key Points: 
  • This change now requires these medications, such as Oxytetracycline, Sulfisoxazole, Erythromycin, and others to be obtained with a prescription from a licensed veterinarian.
  • Many farmers don’t have time for this extra step, especially during critical periods, such as the ongoing calving season.
  • "Urgency in obtaining affordable prescriptions for your animals, especially during calving season, is crucial," stresses Steve McCombs, Buyer at Blain's Farm & Fleet.
  • "The introduction of farmandfleetrx.com stands as a dynamic and essential resource, aiding animal owners in effortlessly navigating the new regulatory landscape.

Shield Your Herd: University Products Leads the Charge with Premier Bovine Anaplasmosis Vaccine

Retrieved on: 
Tuesday, April 9, 2024
Cattle, Depression, Southeastern United States, Parasitism, Jaundice, Farmer, PDF, Pressure, Gland, Face, Abortion, Biting, Disease, Infection, Anaplasmosis, Tick, Anaplasma, Prescription, Death, Veterinarian, Fever, Needle, Blood, FDA, Animal, Vaccine

Rising Threat: Anaplasmosis Expands Across the U.S.

Key Points: 
  • Rising Threat: Anaplasmosis Expands Across the U.S.
    Anaplasmosis in cattle is primarily spread from the bites of infected ticks and horseflies.
  • "And despite widespread industry use, antibiotics were never meant to be a routine preventative cure," said Gene Luther from University Products.
  • And University Products' Anaplasmosis vaccine remains the optimal choice.
  • For more information on vaccine availability for ranchers and veterinarians, please contact University Products directly.

AMYLYX PHARMACEUTICALS, INC. (NASDAQ: AMLX) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Amylyx Pharmaceuticals, Inc.

Retrieved on: 
Monday, March 25, 2024
Apoptosis, ALS, District court, Patient, AMX0035, News, Prescription, Complaint, Action Replay, Amylyx Pharmaceuticals, Food, Court, Advertising, Pharmaceutical industry

If you purchased or acquired Amylyx securities, and/or would like to discuss your legal rights and options please visit Amylyx Pharmaceuticals, Inc.

Key Points: 
  • If you purchased or acquired Amylyx securities, and/or would like to discuss your legal rights and options please visit Amylyx Pharmaceuticals, Inc.
  • If you wish to serve as lead plaintiff, you must move the Court no later than April 9, 2024.
  • A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
  • The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414.

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Amylyx Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines – AMLX

Retrieved on: 
Saturday, March 23, 2024
Prior, Apoptosis, ALS, District court, Patient, AMX0035, Amyotrophy, Ext, LLP, Prescription, IBD, Complaint, Pomerantz, Action Replay, Food, Court, Evercore, Person, Pharmaceutical industry

NEW YORK, March 23, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Amylyx Pharmaceuticals, Inc.  (“Amylyx” or the “Company”) (NASDAQ: AMLX) and certain officers.

Key Points: 
  • NEW YORK, March 23, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Amylyx Pharmaceuticals, Inc.  (“Amylyx” or the “Company”) (NASDAQ: AMLX) and certain officers.
  • To discuss this action, contact Danielle Peyton at [email protected] or 646-581-9980 (or 888.4-POMLAW), toll-free, Ext.
  • Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Cassava, NYCB, Amylyx, and InMode and Encourages Investors to Contact the Firm

Retrieved on: 
Friday, March 22, 2024
Apoptosis, Patient, AMX0035, Science, New York Community Bank, NYCB, P.C, Initiative, ACL, Scientific misconduct, IBD, Confidentiality, Safety, Injury, Data management, Food, Signature, Cassava Sciences, ALS, Alzheimer's disease, Defendant, Food and Drug Administration, Journal, Amyotrophy, News, Prescription, Amylyx Pharmaceuticals, Dentist, FDA, City University, Biomarker, Dermatology, Complaint, Investor's Business Daily, Neurobiology of Aging, Cognition, Assumption, Category, BBC World Service, Evercore, Cassava, Pharmaceutical industry

The Company's lead therapeutic drug candidate is PTI-125 (or "simufilam"), a small molecule drug for the proposed treatment of Alzheimer's disease.

Key Points: 
  • The Company's lead therapeutic drug candidate is PTI-125 (or "simufilam"), a small molecule drug for the proposed treatment of Alzheimer's disease.
  • However, in response, Cassava denied the allegations in the Citizen Petition and instead touted the effectiveness of simufilam and the efficacy of the Company's research programs.
  • On this news, Cassava's stock price fell $2.68 per share, or 15.28%, to close at $14.86 per share on October 13, 2023.
  • For more information on the InMode class action go to: https://bespc.com/cases/INMD

ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Amylyx

Retrieved on: 
Tuesday, March 19, 2024
Patient, LLP, Prescription, IBD, Investor's Business Daily, Amylyx Pharmaceuticals, Advertising, Court, BBC World Service, Evercore, Pharmaceutical industry

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia.

Key Points: 
  • Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia.
  • The firm has recovered hundreds of millions of dollars for investors since its founding in 1995.
  • Faruqi & Faruqi, LLP also encourages anyone with information regarding Amylyx’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
  • The law firm responsible for this advertisement is Faruqi & Faruqi, LLP ( www.faruqilaw.com ).

AMYLYX PHARMACEUTICALS, INC. (NASDAQ: AMLX) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Amylyx Pharmaceuticals, Inc.

Retrieved on: 
Monday, March 18, 2024
Apoptosis, ALS, District court, Patient, AMX0035, News, Prescription, Complaint, Action Replay, Amylyx Pharmaceuticals, Food, Court, Advertising, Pharmaceutical industry

If you purchased or acquired Amylyx securities, and/or would like to discuss your legal rights and options please visit Amylyx Pharmaceuticals, Inc.

Key Points: 
  • If you purchased or acquired Amylyx securities, and/or would like to discuss your legal rights and options please visit Amylyx Pharmaceuticals, Inc.
  • If you wish to serve as lead plaintiff, you must move the Court no later than April 9, 2024.
  • If you purchased or acquired Amylyx securities, and/or would like to discuss your legal rights and options please visit Amylyx Pharmaceuticals, Inc.
  • The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414.